Methotrexate reduces the incidence of severe acute graft-versus-host disease without increasing the risk of relapse after reduced-intensity allogeneic stem cell transplantation from unrelated donors

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1, 2011, Pages 93-100

  Vigouroux, Stéphane ^a   Tabrizi, Reza ^a   Melot, Cyril ^a   Coiffard, Joelle ^a   Lafarge, Xavier ^b   Marit, Gérald ^a   Bouabdallah, Krimo ^a   Pigneux, Arnaud ^a   Leguay, Thibaut ^a   Dilhuydy, Marie Sarah ^a   Schmitt, Anna ^a   Boiron, Jean Michel ^b   Milpied, Noël ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Graft versus host disease; Methotrexate; Reduced intensity allogeneic transplantation

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; FOLINIC ACID; METHOTREXATE; THYMOCYTE ANTIBODY; TREOSULFAN; ANTINEOPLASTIC ANTIMETABOLITE; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GRAFT RECIPIENT; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; MYELOPROLIFERATIVE DISORDER; ORGAN DONOR; OVERALL SURVIVAL; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK REDUCTION; SURVIVAL RATE; ACUTE DISEASE; ALLOTRANSPLANTATION; DONOR; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; METHODOLOGY; MIDDLE AGED;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; METHOTREXATE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 79956207399     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.06.013     Document Type: Article

References (25)

1. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
2. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigenidentical siblings versus human leukocyte antigen-allelicmatched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24:5695-5702.
3. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versushost disease prophylaxis with or without anti-T-cell globulin in hematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855-864.
4. Schmitz N, Beksac M, Hasenclever D, et al. European Group for Blood and Marrow Transplantation. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002;100:761-767.
5. Sullivan KM, Dykewicz CA, Longworth DL, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program. 2001;392-421.
6. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
7. Schulman HM, Sullivan KM, Weiden PL, et al. Chronic graftversus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
8. Casper J, Knauf W, Kiefer T, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood. 2004;103:725-731.
9. Kröger N, Shimoni A, Zabelina T, et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant. 2006;37:339-344.
10. Schmidt-Hieber M, Blau IW, Trenschel R, et al. Reducedtoxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2007;39:389-396.
11. Weisdorf D, Hakke R, Blazar B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991;51:1197-1203.
12. Storb R, Pepe M, Deeg HJ, et al. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graftversus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood. 1992;80:560-561.
13. Sorror ML, Leisenring W, Deeg HJ, Martin PJ, Storb R. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biol Blood Marrow Transplant. 2005;11:814-815.
14. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993;329:1225-1230.
15. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and shortterm methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood. 2000;96:1690-1697.
16. Zikos P, Van Lint MT, Frassoni F, et al. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood. 1998; 91:3503-3608.
17. Ho VT, Aldridge J, Kim HT, et al. Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and minimethotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:844-850.
18. Uberti JP, Ayash L, braun T, Reynolds C, Silver S, Ratanatharathorn V. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. Bone Marrow Transplant. 2004;34: 425-431.
19. Aschan J, Ringdén O, Sundberg B, Gahrton G, Ljungman P, Winiarski J. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant. 1991;7: 113-119.
20. Iravani M, Mousavi A, Gholibeikian S, et al. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versushost disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation. Bone Marrow Transplant. 2005;35:1095-1099.
21. Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;34:621-615.
22. Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2005;11:495-505.
23. Pérez-Simón JA, Martino R, Caballero D, et al.Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graftversus-host disease prophylaxis. Biol Blood Marrow Transplant. 2008;14:664-671.
24. Christopeit M, Schütte V, Theurich S, Weber T, Grothe W, Behre G. Rituximab reduces the incidence of acute graftversus-host disease. Blood. 2009;113:3130-3131.
25. Iori AP, Torelli GF, De Propris MS, et al. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation. 2008;85:386-390.